Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.5K citations · Full text

Medicine, Oncology, Pharmacology +17

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao, Vincent A. Miller, Maureen F. Zakowski et al. · Proceedings of the National Academy of Sciences · 2004 · 4.3K citations · Full text

Medicine, Molecular Genetics, Oncology +16

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

William Pao, Vincent A. Miller, Katerina Politi et al. · PLoS Medicine · 2005 · 3.5K citations · Full text

Medicine, Oncology, Pharmacology +17

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Cai‐Hong Yun, Kristen E. Mengwasser, Angela V. Toms et al. · Proceedings of the National Academy of Sciences · 2008 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +14

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Román Pérez-Soler, Abraham Chachoua, Lisa A. Hammond et al. · Journal of Clinical Oncology · 2004 · 1.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +16